Technologies
PDF


WARF: P03366US

Cytomegalovirus Disintegrin-Like Peptides


INVENTORS -

Teresa Compton, Adam Feire

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing methods to inhibit the entry of viruses, such as herpesvirus, into host cells.
OVERVIEWAlthough human cytomegalovirus (HCMV) is capable of binding, penetrating, and initiating replication in all vertebrate cell types tested, the precise mechanism this virus uses to enter cells remains unknown. Integrins are cell surface receptors involved in the entry of many viruses into cells; however, HCMV does not contain any classic integrin-binding domains. One of the HCMV glycoproteins, glycoprotein B, plays a crucial role in attachment and fusion with the host cell.
THE INVENTIONUW-Madison researchers have developed methods to inhibit the entry of viruses, such as herpesvirus, into host cells, thus preventing viral infection. They identified a conserved integrin-binding, disintegrin-like domain in glycoprotein B that engages integrins and facilitates internalization of viruses into the host cell. Synthetic versions of this disintegrin-like peptide sequence, as well as antibodies against these sequences, block entry of HCMV into cells. They are potential antiviral agents for all members of the beta herpesvirus subfamily, including HCMV and human herpesvirus-6, which cause many chronic ailments and diseases.
APPLICATIONS
  • Preventing or treating infection with HCMV, human herpesvirus-6, and other members of the beta herpesvirus subfamily
  • Studying integrins
  • May provide anti-cancer therapies
KEY BENEFITS
  • Provides the first known disintegrin-like domain involved in viral entry
ADDITIONAL INFORMATION
Related Intellectual Property
Contact Information
For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.